High materiality9/10
Faeth Therapeutics initiated with an Outperform at Baird
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Faeth Therapeutics received an Outperform rating from Baird with a $57 price target.
- Faeth Therapeutics: Outperform at Baird; target $57 (price $24.67)
Key facts
- 01
Target: $57
- 02
Posted price: $24.67
- 03
Analyst firm: Robert W. Baird
- 04
Analyst: Jack Allen
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.